Planet Biotechnology Incorporated
Recombinant fusion proteins combining immunoglobulin Fc domains with Factor H short consensus repeats to block pathogen complement evasion and promote immune killing
- Sector
- Biotech
- Headquarters
- Hayward, CA
- Total capital
- $19M
- Federal grants
- $18.1M
- 34 awards · 2015–2025
- Rank in peer group#81 of 514
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $828K
- 2 awards · Defense, Health and Human S
- Rank in Biotech#201 of 4373
- Granted patents
- None on recordNo USPTO grants. Applications publish after 18 months.
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Bispecific antibody for topical administration to prevent gonorrhea$300K
- Federal grantHealth and Human S · Phase I · Factor H-Fc Fusion as a Pre-Exposure Prophylactic for Rickettsia Infections$295K
- Federal grantHealth and Human S · Phase I · Developing a Potent Broad-Spectrum Prophylactic for Tickborne Disease$300K
- Federal grantHealth and Human S · Phase I · A broad spectrum anti-gonorrhea immunotherapeutic$297K
- Federal grantHealth and Human S · Phase I · Bispecific antibody for topical administration to prevent gonorrhea$300K
- Federal grantHealth and Human S · Phase I · Factor H Fc fusions as novel therapeutics for Burkholderia pseudomallei infections$300K
- Federal grantHealth and Human S · Phase I · Developing a Potent Broad-Spectrum Prophylactic for Tickborne Disease$300K
Show 29 earlier federal awards
- Federal grantHealth and Human S · Phase I · Factor H-Fc Fusion as a Pre-Exposure Prophylactic for Rickettsia Infections$300K
- Federal grantHealth and Human S · Phase I · A broad spectrum anti-gonorrhea immunotherapeutic$300K
- Federal grantHealth and Human S · Phase I · Factor H Fc fusions as novel therapeutics for Burkholderia pseudomallei infections$300K
- Federal grantHealth and Human S · Phase I · Factor H Fc fusions as novel therapeutics for Burkholderia pseudomallei infections$300K
- Federal grantHealth and Human S · Phase II · FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease$1M
- Federal grantHealth and Human S · Phase II · FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease$1M
- Federal grantHealth and Human S · Phase II · FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease$2M
- Federal grantHealth and Human S · Phase I · FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease$182K
- Federal grantHealth and Human S · Phase II · An immunotherapeutic to prevent gonorrhea$929K
- Federal grantHealth and Human S · Phase I · FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease$263K
- Federal grantHealth and Human S · Phase I · FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease$445K
- Federal grantHealth and Human S · Phase I · Recombinant Fc fusions for treatment of uropathogenic E. coli$487K
- Federal grantHealth and Human S · Phase I · Recombinant Fc fusions for treatment of uropathogenic E. coli$487K
- Federal grantHealth and Human S · Phase II · An immunotherapeutic to prevent gonorrhea$798K
- Federal grantHealth and Human S · Phase II · An immunotherapeutic to prevent gonorrhea$1.7M
- Federal grantHealth and Human S · Phase I · Improving gene expression via Massively Parallel Synonymous Codon Variant Screening$299K
- Federal grantHealth and Human S · Phase I · Improving gene expression via Massively Parallel Synonymous Codon Variant Screening$299K
- Federal grantHealth and Human S · Phase II · An immunotherapeutic to prevent gonorrhea$300K
- Federal grantHealth and Human S · Phase I · An immunoadhesin therapy for glioblastoma targeting CD97$264K
- Federal grantHealth and Human S · Phase I · An immunoadhesin therapy for glioblastoma targeting CD97$264K
- Federal grantHealth and Human S · Phase I · A mucosally targeted MERS-CoV vaccine produced in plants$236K
- Federal grantHealth and Human S · Phase I · A mucosally targeted MERS CoV vaccine produced in plants$236K
- Federal grantHealth and Human S · Phase I · A novel anti-gonorrhea immunotherapeutic$242K
- Federal grantHealth and Human S · Phase I · A novel anti gonorrhea immunotherapeutic$242K
- Federal grantHealth and Human S · Phase II · A MERS-CoV Receptor Decoy$773K
- Federal grantHealth and Human S · Phase II · A MERS-CoV Receptor Decoy$1.6M
- Federal grantHealth and Human S · Phase II · A MERS-CoV Receptor Decoy$802K
- Federal contractHealth and Human S · Igf::cl::igf$150K
- Federal contractDefense · 500 Mg Of ATCRY1 Cryptochrome Protein And 500 Mg Of Gwcryla Cryptochrome Protein$678K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#81 · top 16%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
No granted patents are on record.
USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.
Checked: USPTO granted patents and published applications · Oct 23, 2026
Related companies, and why
- INTRA-CELLULAR THERAPIES, INC.Similar federal contract value in Biotech · $849K in contracts
- ENERGESIS PHARMACEUTICALS INCSimilar federal contract value in Biotech · $849K in contracts
- SECOND GENOME, INC.Similar federal contract value in Biotech · $834K in contracts
- SUJANA BIOTECH, LLCSimilar federal contract value in Biotech · $783K in contracts
- JUMPCODE GENOMICSSimilar federal contract value in Biotech · $765K in contracts
- GenomaticaSimilar federal contract value in Biotech · $761K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .